Abstract
Patients with schizophrenia exhibit a deficit in mismatch negativity (MMN) and reduced auditory steady-state response (ASSR). As part of a Phase II trial investigating efficacy and safety of the novel glycine transporter 1 inhibitor BI 425809 in patients with schizophrenia, these and other electroencephalography (EEG) parameters were evaluated as potential diagnostic, predictive, or treatment response biomarkers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
